Kristine D Harper
Overview
Explore the profile of Kristine D Harper including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
440
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nauck M, Frossard J, Barkin J, Anglin G, Hensley I, Harper K, et al.
Diabetes Care
. 2017 Mar;
40(5):647-654.
PMID: 28283565
Objective: To assess the risk of acute pancreatitis during treatment with glucagon-like peptide 1 receptor agonist dulaglutide, placebo, and active comparators across phase 2/3 dulaglutide trials. Research Design And Methods:...
2.
Tuttle K, McKinney T, Davidson J, Anglin G, Harper K, Botros F
Diabetes Obes Metab
. 2016 Oct;
19(3):436-441.
PMID: 27766728
Dulaglutide is a once-weekly glucagon-like peptide-1 receptor agonist approved for the treatment of type 2 diabetes (T2D). Integrated data from 9 phase II and III trials in people with T2D...
3.
Harper K, Krege J, Marcus R, Mitlak B
J Bone Miner Res
. 2006 Nov;
22(2):334.
PMID: 17129179
No abstract available.
4.
Harper K, Krege J, Marcus R, Mitlak B
Curr Med Res Opin
. 2006 Oct;
22(10):1927.
PMID: 17022851
No abstract available.
5.
Delmas P, Ensrud K, Adachi J, Harper K, Sarkar S, Gennari C, et al.
J Clin Endocrinol Metab
. 2002 Aug;
87(8):3609-17.
PMID: 12161484
The Multiple Outcomes of Raloxifene Evaluation trial studied 7705 postmenopausal women with osteoporosis randomized to placebo, or raloxifene 60 or 120 mg/d [JAMA 282(1999): 637]. This report assesses the efficacy...
6.
Maricic M, Adachi J, Sarkar S, Wu W, Wong M, Harper K
Arch Intern Med
. 2002 May;
162(10):1140-3.
PMID: 12020184
Background: Raloxifene hydrochloride therapy reduces the risk for vertebral fractures at 3 years, but the effects on clinical vertebral fractures in the first year are not known. Methods: The Multiple...
7.
Barrett-Connor E, Grady D, Sashegyi A, Anderson P, Cox D, Hoszowski K, et al.
JAMA
. 2002 Feb;
287(7):847-57.
PMID: 11851576
Context: Raloxifene, a selective estrogen receptor modulator, improves cardiovascular risk factors, but its effect on cardiovascular events is unknown. Objective: To determine the effect of raloxifene on cardiovascular events in...
8.
Sarkar S, Mitlak B, Wong M, Stock J, Black D, Harper K
J Bone Miner Res
. 2002 Jan;
17(1):1-10.
PMID: 11771654
Although low absolute values of bone mineral density (BMD) predict increased fracture risk in osteoporosis, it is not certain how well increases in BMD with antiresorptive therapy predict observed reductions...